New treatment options for pneumonia

Infections in Medicine

Volumn 15, Issue 8 SUPPL. E, 1998, Pages 34-45

  Mandell, Lionel A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Acute exacerbation of chronic bronchitis (AECB); Antimicrobial resistance; Atypical pneumonia; Community acquired pneumonia (CAP); Fluoroquinolones; Mycoplasma pneumnoniae; Streptococcus pneumoniae

Indexed keywords

EID: 0001913717     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Dixon RE: Economic costs of respiratory tract infections in the United States. Am J Med 78:45, 1985.
2. National Center for Health Statistics: National hospital discharge survey: Annual summary 1990. Vital Health Stat 13:1-225, 1992.
3. CDC: Pneumonia and influenza death rates: United States 1979-1994. MMWR 44:535-537, 1995.
4. Fine MJ, Smith MA, Carson CA, et al: Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 275:134-141, 1996.
5. The British Thoracic Society: Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 49:346-350, 1993.
6. Marston BJ, Plouffe JF, File TM, et al: Incidence of community-acquired pneumonia requiring hospitalizations: Results of a population-based active surveillance study in Ohio. Arch Intern Med 157:1709-1718, 1997.
7. Fang GD, Fine M, Orloff J, et al: New and emerging etiologies for community-acquired pneumonia with implications for therapy; a prospective multicenter study of 359 cases. Medicine (Baltimore) 69:307-316, 1990.
8. Marrie TJ, Durant H, Yates L: Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 11:586-599, 1989.
9. Mundy LM, Auwaerter PG, Oldach D, et al: Community-acquired pneumonia: Impact of immune status. Am J Respir Crit Care Med 152:1309-1315, 1995.
10. Keller DW, Lipman HB, Marston BJ, et al: Clinical diagnosis of Legionnaires' disease (LD) using a multivariate model. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, Calif., Sept. 17-20, 1995. Abstract K55.
11. Berntsson E, Lagergard T, Strannegard O, et al: Etiology of community-acquired pneumonia in outpatients. Eur J Clin Microbiol 5:446, 1986.
12. Marrie TJ, Peeling RW, Fine MJ, et al: Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 101:508, 1996.
13. Erard PH, Moser F, Wenger A, et al: Prospective study on community-acquired pneumonia diagnosed and followed up by private practitioners. CHUV, Lausanne, Switzerland. Abstracts of the 31st ICAAC, Chicago, Ill., October 1991. Abstract 56.
14. Langille DB, Yates L, Marrie TJ: Serological investigation of pneumonia as it presents to the physician's office. Can J Infect Dis 4:328, 1993.
15. Moine P, Vercken J-B, Chevret S, et al: Severe community-acquired pneumonia: Etiology, epidemiology, and prognostic factors. Chest 105:1487-1495, 1994.
16. Pachon J, Prados MD, Capote F, et al: Severe community-acquired pneumonia: Etiology, prognosis and treatment. Am Rev Respir Dis 142:369-373, 1990.
17. Garb JL, Brown RB, Garb JR, et al: Differences in etiology of pneumonias in nursing home and community patients. JAMA 240:2169, 1978.
18. Phillips SL, Branaman-Phillips J: The use of intramuscular cefoperazone versus intramuscular ceftriaxone in patients with nursing home acquired pneumonia. J Am Geriatr Soc 41:1071, 1993.
19. Chow CW, Senthiragah N, Rawji M, et al: Interim report on drug utilization review of community-acquired and nosocomial pneumonia: Clinical, bacteriological and radiological spectrum. Can J Infect Dis 5(suppl C):20C, 1994.
20. CDC: Defining the public health impact of drug-resistant S pneumoniae: Report of a working group. MMWR 45(RR-1 suppl):1-20, 1996.
21. Fang GD, Yu VL, Vickers RM: Disease due to Legionellaceae (other than Legionella pneumophila): Historical, microbiological, clinical and epidemiological review. Medicine 68:116-132, 1989.
22. Woodhead MA, Macfarlane JT: Comparative clinical and laboratory features of Legionella with pneumococcal and Mycoplasma pneumonias. Br J Dis Chest 81:133-139, 1987.
23. Farr BM, Kaiser DL, Harrison BDW, et al: Prediction of microbial aetiology at admission to hospital from the presenting clinical features. Thorax 44:1031-1035, 1989.
24. Macfarlane J: An overview of community acquired pneumonia with lessons learned from the British Thoracic Society study. Semin Respir Infect 9:153-165, 1994.
25. San Pedro GS, Campbell GD Jr: Limitations of diagnostic testing in the initial management of patients with community-acquired pneumonia. Semin Respir Infect 12:300-307, 1997.
26. Barrett-Conner E: The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis 103:845-848, 1971.
27. Halinski D, Bartelt M, Campbell GD Jr, et al: Failure of sputum grading to improve diagnosis in blood-culture-positive pneumonias. Chest 102(suppl):110S, 1992.
28. Reed WW, Byrd GS, Gate HR Jr, et al: Sputum Gram's stain in community-acquired pneumococcal pneumonia: A meta-analysis. West J Med 165:197-204, 1996.
29. Mandell LA, Niederman M, The Canadian Community Acquired Pneumonia Consensus Conference Group: Antimicrobial treatment of community acquired pneumonia in adults: A conference report. Can J Infect Dis 4:25-28, 1993.
30. Niederman MS, Bass JB Jr, Campbell GD Jr, et al: Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 148:1418-1426, 1993.
31. Gordon G, Throop D, Berberian L, et al: Validation of the American Thoracic Society (ATS) guidelines for community-acquired pneumonia in hospitalized patients. Am J Respir Crit Care Med 15(suppl):A257, 1995.
32. Bateman K, Dean NC, Hadlock CJ, et al: Use of a care process model (CPM) for community-acquired pneumonia in a rural area. Chest 110(suppl):30S, 1996.
33. Bartlett JG, O'Keefe P, Talley F, et al: Bacteriology of hospital-acquired pneumonia. Arch Intern Med 146:868-871, 1986.
34. Bartlett JG, Breiman RF, Mandell LA, et al: Community-acquired pneumonia in adults: Guidelines for management. Clin Infect Dis. In press.
35. Leroy O, Santre C, Beuscart C: A 5-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an ICU. Intensive Care Med 21:24-31, 1995.
36. Levy M: Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations. Chest 92:43-48, 1988.
37. Friedland IR, McCracken GH Jr: Management of infections caused by antibiotic-resistant Streptococcus pneumoniae (see comments). N Engl J Med 331:377-382, 1994.
38. Rahav G, Toledano Y, Engelhard D, et al: Invasive pneumococcal infections: A comparison between adults and children. Medicine (Baltimore) 76:295-303, 1997.
39. Morgenroth J, Kaufman M: Arzneifestigkeit bei Bakterien (Pneumokokken). Zeitschr Immunitatsforsch 15:610-624, 1912.
40. Moore HF, Chesney AM: A study of ethylhydrocuprein (optochin) in the treatment of acute lobar pneumonia. Arch Intern Med 19:611-682, 1917.
41. Ross RW: Acquired tolerance of pneumococcus to M. & B. 693. Lancet 1:1207-1209, 1939.
42. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing. Villanova, Pa., National Committee for Laboratory Standards, 1994. NCCLS document M100-S5 supplement, vol 24, no 16.
43. Hansman D, Bullen MM: A resistant pneumococcus. Lancet 2:264, 1967. Letter.
44. Hansman D: Type distribution and antibiotic sensitivity of pneumococci from carriers in Kiriwina, Trobriand Islands (New Guinea). Med J Aust 2:771-773, 1972.
45. Naraqi S, Kirkpatrick GP, Kabins S: Relapsing pneumococcal meningitis: Isolation of an organism with decreased susceptibility to penicillin G. J Pediatr 85:671-673, 1974.
46. Lapointe J, Joncas JH: Meningitis in a Canadian infant due to pneumococcus resistant to penicillin and chloramphenicol. J Pediatr 103:580-582, 1983.
47. Ballow CH, Jones RN, Johnson D, et al: Regional trends in S pneumoniae resistance: Results of a nationwide, multi-center trial. Abstracts of the 37th ICAAC, Toronto, Ontario, Canada, Sept. 28-Oct. 1, 1997. Abstract E-118.
48. Thornsberry C, Ogilvie P, Kahn JB, et al: Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 29:249-257, 1997.
49. Johnston NJ, deAzavedo JC, Kellner JD, et al: Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in Streptococcus pneumoniae from across Canada. Abstracts from the 37th ICAAC, Toronto, Ontario, Canada, Sept. 28-Oct. 1, 1997. Abstract C-77a.
50. Jacobs MR, Koornhof HJ, Robbins-Browne RM, et al: Emergence of multiply resistant pneumococci. N Engl J Med 299:735-740, 1978.
51. McDougal LK, Facklam R, Reeves M, et al: Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States. Antimicrob Agents Chemother 36:2176-2184, 1992.
52. Doern GV, Brueggemann A, Holley HP Jr, et al: Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208-1213, 1996.
53. Livermore DM: Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557-584, 1995.
54. Jacoby GA, Carreras I: Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 34:838-862, 1990.
55. Henquell C, Chanal C, Sirot D, et al: Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother 39:427-430, 1995.
56. Stapleton P, Wu PJ, King A, et al: Incidence and mechanism of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 39:2478-2483, 1995.
57. Friedland IR, Klugman KP: Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 146:920-923, 1992.
58. Pallares R, Linares J, Vadillo M, et al: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 333:474-480, 1995.
59. Klugman KP: The clinical relevance of in-vitro resistance to penicillin, ampicillin, amoxicillin and alternative agents, for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilia influenzae and Moraxella calarrhalis. J Antimicrob Chemother 38(suppl A):S133-S140, 1996.
60. Klugman KP: Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3:171-196, 1990.
61. Garibaldi RA: Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impact. Am J Med 78 (suppl 6B):S32-S37, 1985.
62. Verheij TJM, Kaptein AA, Mulder JD: Acute bronchitis: Etiology, symptoms and treatment. J Fam Pract 6:66-69, 1989.
63. Turner-Warwick M, Hodson ME, Corrin B, et al: Clinical Atlas of Respiratory Diseases. London, Gower Medical Publishing, 1990.
64. Fisher M, Akhtar AJ, Calder MA, et al: Pilot study of factors associated with exacerbations of chronic bronchitis. Br Med J 4:187-192, 1969.
65. Musher DM, Kubitschek KR, Crennan J, et al: Pneumonia and acute febrile tracheobronchitis due to Haemophilus influenzae. Ann Intern Med 99:444-450, 1983.
66. Stockley RA, Burnett D: Serum-derived protease inhibitors and leucocyte elastase in sputum and the effect of infections. Bull Eur Physiopathol Respir 16:261-271, 1980.
67. Gump DW, Phillips CA, Forsyth BR, et al: Role of infection in chronic bronchitis. Am Rev Respir Dis 113:465-473, 1976.
68. Monso E, Ruiz J, Rosell A, et al: Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 152:1316-1320, 1995.
69. Fagon JY, Chastre J, Trouillet JL, et al: Characterization of the distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 142:1004-1008, 1990.
70. Hill S, Pye A, Johnson MM, et al: A role for Haemophilus parainfluenzae in chronic lung disease. Am J Respir Crit Care Med 155(suppl):A105, 1997.
71. Anthonisen NR, Manfreda J, Warren CP, et al: Antibiotic therapy in exacerbations of chronic obstructive lung disease. Ann Intern Med 106:196-204, 1987.
72. Saint S, Vittinghoff E, Grady D: Antibiotics in chronic obstructive pulmonary disease exacerbations: A meta-analysis. JAMA 273:957-960, 1995.
73. Seneff MG, Wagner DP, Wagner RP, et al: Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive lung disease. JAMA 274:1852-1857, 1995.
74. Balter MS, Hyland RH, Low DE, et al: Recommendations on the management of chronic bronchitis. Can Med Assoc J 151(suppl):S7-S23, 1994.
75. Lode H: Respiratory tract infections: When is antibiotic therapy indicated? Clin Ther 13:149-156, 1991.
76. Wilson R: Outcome predictors in bronchitis. Chest 108(suppl):S53-S57, 1995.
77. Grossman RF, Vaughan D, Mukerjee J, et al: The ciprofloxacin health economic study (CHEST). Am J Respir Crit Care Med 155(suppl):A105, 1997.
78. Ramirez JA: Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 22:219-223, 1995.